文献速递妇科

重大妇科癌症中的T细胞靶抗原

T-cell target antigens across major gynecologic cancers.
PubMed 文献 · Gynecol Oncol · 2017-04-02

综述探讨妇科癌症(卵巢癌、宫颈癌、子宫内膜癌)免疫治疗中T细胞靶抗原的选择,分析共享抗原、病毒抗原和患者特异性突变抗原的优缺点,指出尽管肿瘤限制性抗原鉴定困难,但靶向这些抗原的T细胞疗法可能改善患者结局。

要点

  • 妇科癌症可引发内源性抗肿瘤免疫反应,早期试验中免疫治疗已取得 modest 临床成功。
  • 与高突变负荷实体瘤或血液恶性肿瘤不同,妇科肿瘤的肿瘤限制性抗原鉴定具有挑战性。
  • 靶向共享、病毒或患者特异性突变抗原的T细胞疗法可能改善妇科癌症患者结局。

核心结论

  • 越来越多的临床前和临床证据表明,用T细胞靶向妇科肿瘤表达的共享抗原、病毒抗原或患者特异性突变抗原可能改善患者结局。

研究设计与样本

  • 综述,检索范围未在摘要中报告。

主要发现

  • 免疫检查点阻断或基因工程T细胞在黑色素瘤、非小细胞肺癌、膀胱癌、滑膜细胞肉瘤和多发性骨髓瘤中取得显著成功。
  • 妇科癌症历史上未被归类为免疫原性肿瘤,但 growing evidence 显示其能引发内源性抗肿瘤免疫反应。
  • 使用免疫治疗模式治疗卵巢癌、宫颈癌和子宫内膜癌等主要妇科癌症的早期试验已取得 modest 临床成功。
  • 与高突变负荷实体瘤或靶抗原均匀且专属表达的血液恶性肿瘤不同,为妇科肿瘤设计T细胞靶向疗法时鉴定肿瘤限制性抗原具有挑战性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunotherapies have achieved remarkable success in treating different forms of cancer including melanoma, non-small cell lung carcinoma, bladder cancer, synovial cell sarcoma, and multiple myeloma using immune checkpoint blockade or gene-engineered T-cells. Although gynecologic cancers have not been historically classified as immunogenic tumors, growing evidence has shown that they are in fact able to elicit endogenous antitumor immune responses suggesting that patients with these cancers may benefit from immunotherapy. Modest clinical success has been accomplished in early trials using immunotherapeutic modalities for major gynecologic cancers including ovarian, cervical, and endometrial cancer. Unlike solid cancers with high mutational burdens, or hematologic malignancies where target antigens are expressed homogenously and exclusively by tumor cells, identifying tumor-restricted antigens has been challenging when designing a T-cell targeted therapy for gynecologic tumors. Nevertheless, mounting preclinical and clinical evidence suggests that targeting shared, viral or patient-specific mutated antigens expressed by gynecologic tumors with T-cells may improve patient outcome. Here we review the strengths and weaknesses of targeting these various antigens, as well as provide insight into the future of immunotherapy for gynecologic cancers.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Rodriguez-Garcia A, Minutolo NG, Robinson JM, et al. T-cell target antigens across major gynecologic cancers. Gynecol Oncol. 2017. PMID: 28377094. doi:10.1016/j.ygyno.2017.03.510

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。